Holen Sie sich die Stockscreener-App
1.71
2.29%
-0.04
Handel nachbörslich:
1.71
Schlusskurs vom Vortag:
$1.75
Offen:
$1.77
24-Stunden-Volumen:
131.14K
Relative Volume:
0.54
Marktkapitalisierung:
$127.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.5463
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
-1.16%
1M Leistung:
-7.57%
6M Leistung:
-23.32%
1J Leistung:
+23.91%
1-Tages-Spanne:
$1.695
$1.88
1-Wochen-Bereich:
$1.415
$1.88
52-Wochen-Spanne:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
678-392-3419
Adresse
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.71 | 130.10M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Using fundamentals and technicals on Inhibikase Therapeutics Inc.Weekly Stock Summary & Risk Adjusted Buy and Sell Alerts - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockJuly 2025 Market Mood & Weekly Setup with High ROI Potential - Newser
Automated trading signals detected on Inhibikase Therapeutics Inc.Portfolio Return Report & Accurate Buy Signal Notifications - Newser
Real time pattern detection on Inhibikase Therapeutics Inc. stockBollinger Band Squeeze and Expansion Analysis - Newser
Blair William & Co. IL Has $342,000 Stake in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Chart based analysis of Inhibikase Therapeutics Inc. trendsHigh Accuracy Trade Setup Identification - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceEarnings Impact and Stock Reaction Analysis - Newser
Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Short-Term Support and Resistance Forecast - Newser
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free Watchlist for Smart Swing Trading - Newser
Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser
What indicators show strength in Inhibikase Therapeutics Inc.Free Real Market Momentum Signal Generator - Newser
How high can Inhibikase Therapeutics Inc. stock goMonthly Long-Term Market Recap and Summary - Newser
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Tactical Trade Setup With Entry Optimizer - Newser
Inhibikase Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
What risks could impact Inhibikase Therapeutics Inc. stock performanceFree Weekly Potential Breakout Stock List - Newser
Inhibikase Therapeutics Inc. recovery potential after sell offSmart Risk Strategy with Entry Optimization - Newser
How Inhibikase Therapeutics Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser
Published on: 2025-08-06 00:58:01 - Newser
Published on: 2025-08-04 16:30:58 - metal.it
What institutional investors are buying Inhibikase Therapeutics Inc. stockMarket-leading capital gains - Jammu Links News
How does Inhibikase Therapeutics Inc. compare to its industry peersOutstanding capital growth - Jammu Links News
Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedFastest return on investment - Jammu Links News
What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News
When is Inhibikase Therapeutics Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - Jammu Links News
What are the latest earnings results for Inhibikase Therapeutics Inc.Unlock powerful investment tools for free - Jammu Links News
Is it the right time to buy Inhibikase Therapeutics Inc. stockDiscover market opportunities with expert help - Jammu Links News
Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Early Breakout Entry Point Notifications - newser.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):